Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration

Journal of Medicinal Chemistry

Volumn 50, Issue 16, 2007, Pages 3851-3856

  Dziadulewicz, Edward K ^a   Bevan, Stuart J ^a   Brain, Christopher T ^a   Coote, Paul R ^a   Culshaw, Andrew J ^a,c   Davis, Andrew J ^a   Edwards, Lee J ^a   Fisher, Adrian J ^a   Fox, Alyson J ^a   Gentry, Clive ^a   Groarke, Alex ^a   Hart, Terance W ^a   Huber, Werner ^b   James, Iain F ^a   Kesingland, Adam ^a   La Vecchia, Luigi ^b   Loong, Yvonne ^a   Lyothier, Isabelle ^a   McNair, Kara ^a   O'Farrell, Cathal ^a   Peacock, Marcus ^a   Portmann, Robert ^b   Schopfer, Ulrich ^b   Yaqoob, Mohammed ^a   Zadrobilek, Jiri ^b   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; NAPHTHALEN 1 YL (4 PENTYLOXYNAPHTHALEN 1 YL)METHANONE; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CRICETINAE; CRICETULUS; CYCLIC AMP; HUMANS; HYPERALGESIA; MICROSOMES, LIVER; NAPHTHALENES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548096786     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070317a     Document Type: Article

References (44)

1. Voth, E. A.; Schwartz, R. H. Medicinal Applications of Delta-9-tetrahydrocannabinol and Marijuana. Ann. Intern. Med. 1997, 126, 791-798.
2. Watson, S. J.; Benson, J. A., Jr.; Joy, J. E. Marijuana and Medicine: Assessing the Science Base: A Summary of the 1999 Institute of Medicine Report. Arch. Gen. Psychiatry 2000, 57, 547-552.
3. (a) Hall, W.; Solowij, N. Adverse Effects of Cannabis. Lancet 1998, 352, 1611-1616.
4. (b) Fox, A.; Bevan, S. Therapeutic Potential of Cannabinoid Receptor Agonists as Analgesic Agents. Expert Opin. Invest. Drugs 2005, 14, 695-703.
5. Porter, A. C.; Felder, C. C. The Endocannabinoid Nervous System: Unique Opportunities for Therapeutic Intervention. Pharmacol. Ther. 2001, 90, 45-60 and references therein.
6. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature 1990, 346, 561-564.
7. (a) Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61-65.
8. 2 Receptors. Science 2005, 310, 329-332.
9. 2 Receptors: Immunohistochemical Localization in Rat Brain. Brain Res. 2006, 1071, 10-23.
10. Pertwee, R. G. Pharmacology of Cannabinoid Receptor Ligands. Curr. Med. Chem. 1999, 6, 635-664.
11. Rice, A. S. C. Cannabinoids and Pain. Curr. Opin. Invest. Drugs 2001, 2, 399-414.
12. Iversen, L.; Chapman, V. Cannabinoids: A Real Prospect for Pain Relief? Curr. Opin. Pharmacol. 2002, 2, 50-55.
13. Goya, P.; Jagerovic, N.; Hernandez-Folgado, L.; Martin, M. I. Cannabinoids and Neuropathic Pain. Mini Rev. Med. Chem. 2003, 3, 765-772.
14. Bennett, G. J. Neuropathic Pain. In Textbook of Pain, 3rd ed.; Wall, P. D., Melzack, R., Eds.; Churchill Livingstone: New York, 1994; pp 201-224.
15. 1 Receptors in the Antihyperalgesic Activity of Cannabinoids in a Model of Neuropathic Pain. Pain 2001, 92, 91-100.
16. 1 Receptors Inhibits Mechanically Evoked Responses of Spinal Neurons in Noninflamed Rats and Rats with Hindpaw Inflammation. Eur. J. Neurosci. 2003, 18, 2239-2243.
17. (b) Fride, E.; Feigin, C.; Ponde, D. E.; Breuer, A.; Hanǔs, L.; Arshavsky, N.; Mechoulam, R. (+)-Cannabidiol Analogues Which Bind Cannabinoid Receptors but Exert Peripheral Activity Only. Eur. J. Pharmacol. 2004, 506, 179-188.
18. (c) Dyson, A.; Peacock, M.; Chen, B.; Courade, J.-P.; Yaqoob, M.; Groarke, A.; Brain, C.; Loong, Y.; Fox, A. Antihyperalgesic Properties of the Cannabinoid CT-3 in Chronic Neuropathic and Inflammatory Pain States in the Rat. Pain 2005, 116, 129-137.
19. 1 Receptors. Pain 1998, 75, 111-119.
20. 1 Cannabinoid Receptors. Life Sci. 1999, 65, 597-605.
21. (b) Dogrul, A.; Gul, H.; Akar, A.; Yildiz, O.; Bilgin, F.; Guzeldemir, E. Topical Cannabinoid Antinociception: Synergy with Spinal Sites. Pain 2003, 105, 11-16.
22. 2 Receptors Suppresses C-Fiber Responses and Windup in Spinal Wide Dynamic Range Neurons in the Absence and Presence of Inflammation. J. Neurophysiol. 2004, 92, 3562-3574 and references therein.
23. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of Pain Initiation by Endogenous Cannabinoids. Nature 1998, 394, 277-281.
24. Seltzman, H. H. Structure and Receptor Activity for Classical Cannabinoids. Curr. Med. Chem. 1999, 6, 685-704.
25. (a) Hertzog, D. L. Recent Advances in the Cannabinoids. Expert Opin. Ther. Patents 2004, 14, 1435-1452 and previous publications in this series,
26. (b) Padgett, L. W. Recent Developments in Cannabinoid Ligands. Life Sci. 2005, 77, 1767-1798.
27. Johnson, M. R.; Melvin, L. S. In Cannabinoids as Therapeutic Agents; Mechoulam, R., Ed.; CRC Press: Boca Raton, FL, 1986; pp 121-145.
28. (a) Huffman, J. W. Cannabimimetic Indoles, Pyrroles and Indenes. Curr. Med. Chem. 1999, 6, 705-720.
29. (b) Huffman, J. W.; Mabon, R.; Wu, M.-J.; Lu, J.; Hart, R.; Hurst, D. P.; Reggio, P. H.; Wiley, J. L.; Martin, B. R. 3-Indolyl-1-Naphthylmethanes: New Cannabimimetic Indoles Provide Evidence for Aromatic Stacking Interactions with the CB1 Cannabinoid Receptor. Bioorg. Med. Chem. 2003, 11, 539-549.
30. (a) Barth, F.; Rinaldi-Carmona, M. The Development of Cannabinoid Antagonists. Curr. Med. Chem. 1999, 6, 745-755.
31. 1 Cannabinoid Receptor Antagonists. Drug Discovery Today 2005, 10, 693-702.
32. (c) Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists. J. Med. Chem. 1999, 42, 769-776.
33. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other 'Endocannabinoids'. Curr. Med. Chem. 1999, 6, 721-744.
34. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
35. 4 Receptor Ligands. Eur. J. Med. Chem. 2000, 35, 699-706 and references therein.
36. (a) D'Ambra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. Conformationally Restrained Analogues of Pravadoline: Nanomolar Potent, Enantioselective, (Aminoalkyl)indole Agonists of the Cannabinoid Receptor. J. Med. Chem. 1992, 35, 124-135.
37. (b) Howlett, A. C.; Johnson, M. R.; Melvin, L. S.; Milne, G. M. Nonclassical Cannabinoid Analgetics Inhibit Adenylate Cyclase: Development of a Cannabinoid Receptor Model. Mol. Pharmacol. 1988, 33, 297-302.
38. Bell, M. R.; D'Ambra, T. E.; Kumar, V.; Eissenstat, M. A.; Herrmann, J. L., Jr.; Wetzel, J. R.; Rosi, D.; Philion, R. E.; Daum, S. J.; Hlasta, D. J.; Kullnig, R. K.; Ackerman, J. H.; Haubrich, D. R.; Luttinger, D. A.; Baizman, E. R.; Miller, M. S.; Ward, S. J. Antinociceptive (Aminoalkyl)indoles. J. Med. Chem. 1991, 34, 1099-1110.
39. Huffman, J. W.; Dai, D.; Martin, B. R.; Compton, D. R. Design, Synthesis and Pharmacology of Cannabimimetic Indoles. Bioorg. Med. Chem. Lett. 1994, 4, 563-566.
40. 1 Receptor Ligands. PCT Pat. Appl. WO2002042248, 22 November 2001.
41. Unpublished results from these laboratories.
42. Compound 16 and similar anilinic derivatives were synthesized by the Pd/BINAP-catalyzed amination of the aryl triflate derived from compound 10. See Supporting Information and Wolfe, J. P.; Buchwald, S. L. Palladium-Catalyzed Amination of Aryl Triflates. J. Org. Chem. 1997, 62, 1264-1267.
43. 2 Cannabinoid Receptor. J. Pharmacol. Exp. Ther. 1998, 284, 644-650.
44. Costa, B.; Colleoni, M.; Conti, S.; Trovato, A. E.; Bianchi, M.; Sotgiu, M. L.; Giagnoni, G. Repeated Treatment with the Synthetic Cannabinoid WIN 55,212-2 Reduces Both Hyperalgesia and Production of Pronociceptive Mediators in a Rat Model of Neuropathic Pain. Br. J. Pharmacol. 2004, 141, 4-8.